Summary:
- The article announces that FluMist, a nasal spray influenza vaccine, has been approved by the U.S. Food and Drug Administration (FDA) for self-administration by individuals aged 2 to 49 years old.
- This approval allows patients to administer the FluMist vaccine themselves, without the need for a healthcare provider, making it more convenient and accessible for people to get their annual flu shot.
- The article highlights the importance of this approval in improving flu vaccination rates, as self-administration can help overcome barriers such as scheduling appointments and access to healthcare providers, particularly during the COVID-19 pandemic.